目的 探討鼻炎寧膠囊聯(lián)合糠酸莫米松治療慢性鼻炎的有效性和安全性。方法 選取2016年5月—2017年5月在太和縣人民醫(yī)院進(jìn)行治療的慢性鼻炎患者174例，根據(jù)用藥方案不同分成對(duì)照組和治療組，每組各87例。對(duì)照組患者給予糠酸莫米松鼻噴霧劑，4撳/次，1次/d，癥狀明顯緩解后每鼻孔1撳；治療組患者在對(duì)照組的基礎(chǔ)上口服鼻炎寧膠囊，5粒/次，3次/d。兩組患者均治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者鼻阻力、臨床癥狀評(píng)分、生活質(zhì)量評(píng)分、IL-17和IgE水平及不良反應(yīng)。結(jié)果 治療后，對(duì)照組臨床總有效率為87.36%，顯著低于治療組的97.70%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組患者鼻阻力、臨床癥狀評(píng)分和生活質(zhì)量評(píng)分均較治療前顯著降低（P < 0.05）；且治療組患者這些指標(biāo)較對(duì)照組降低得更顯著（P < 0.05）。治療后，兩組患者IL-17、IgE水平均顯著下降（P < 0.05）；且治療組IL-17和IgE水平顯著低于對(duì)照組（P < 0.05）。治療期間，治療組患者不良反應(yīng)發(fā)生率為3.45%，顯著低于對(duì)照組的12.64%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 鼻炎寧膠囊聯(lián)合糠酸莫米松鼻噴劑治療慢性鼻炎具有較好的臨床療效，改善炎癥反應(yīng)水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy and safety of Biyanning Capsules combined with mometasone furoate in treatment of chronic rhinitis. Methods Patients (174 cases) with chronic rhinitis in Taihe County People's Hospital from May 2016 to May 2017 were divided into control and treatment groups based on different treatments, and each group had 87 cases. Patients in the control group were administered with Mometasone Furoate Aqueous Nasal Spray, 4 presses/time, once daily, 1 press each nostril after symptomatic remission. Patients in the treatment group were po administered with Biyanning Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the nasal resistance, clinical symptom scores, quality of life impact scores, IL-17 and IgE levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.36%, which was significantly lower than 97.70% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the nasal resistance, clinical symptom scores, and quality of life impact scores in two groups were significantly decreased (P < 0.05). And these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the IL-17 and IgE levels in two groups were significantly decreased (P < 0.05), and the IL-17 and IgE levels in the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 3.45%, which was significantly lower than 12.64% in the control group, with significant difference between two groups (P < 0.05). Conclusion Biyanning Capsules combined with mometasone furoate has good clinical efficacy in treatment of chronic rhinitis, can significantly improve inflammatory responses, which has a certain clinical application value.